Cavitating pneumonia, a severe complication of leflunomide therapy in chronic polyarthritis [1]

Rheumatology

Volumn 46, Issue 3, 2007, Pages 553-554

  Bruyn, G A W ^a   Jansen, T L ^a   Ten Brinke, A ^a   De Vries, M ^a   Houtman, P M ^a   van Roon, E N ^a  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN A; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE;

ACTINOMYCES; ADULT; AGED; ASPERGILLUS; BACTERIUM ISOLATION; CANDIDA; CAUCASIAN; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; ENTEROBACTER CLOACAE; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; INFORMED CONSENT; LETTER; LOW DRUG DOSE; LUNG CAVITATION; LUNG INFECTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSORIATIC ARTHRITIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RHEUMATOID ARTHRITIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES;

EID: 33847391608     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel397     Document Type: Letter

References (18)

1. Scott DL, Smolen JS, Kalden JR et al. Treatment of active rheumatoid arthritis with leflunomide: Two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23.
2. Van Roon EN, Jansen TL, Mourad L et al. Leflunomide in active rheumatoid arthritis: A prospective study in daily practice. Br J Clin Pharmacol 2004;58:201-8.
3. Kaltwasser JP, Nash P, Gladman D et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
4. Bruyn GAW, Griep EN, Korff KJ. Leflunomide for active rheumatoid arthritis (letter). Lancet 1999;353:1883.
5. Bruyn GAW, Veenstra RP, Halma C, Grond J. Anti-glomerular basement membrane antibody-associated renal failure in a patient with leflunomide-treated active rheumatoid arthritis. Arthritis Rheum 2003;48:1164-5.
6. Kamata Y, Nara H, Kamimura T et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide adverse reaction. Intern Med 2004;43:1201-4.
7. Takeishi M, Akiba H, Adachi D, Hirano M, Mimura T. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005;32:1160-3.
8. Van Roon EN, Yska JP, Raemakers J et al. A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization for leflunomide therapy. J Pharm Biomed Anal 2004;36:17-22.
9. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
10. Arend SM, Kuijper EJ, Allaart CF, Muller WH, Van Dissel JT. Cavitating pneumonia after treatment with infliximab and prednisone. Eur J Clin Microbiol Infect Dis 2004;23:638-41.
11. Kiely PDW, Johnson DM. Infliximab and leflunomide: Combination therapy in rheumatoid arthritis: An open label study. Rheumatology 2002;42:631-7.
12. Cornelissen JJ, Bakker LJ, Van der Veen MJ, Rozenberg-Arska M, Bijlsma JW. Nocardia asteroides pneumonia complicating low dose methotrexate treatment of refractory rheumatoid arthritis. Ann Rheum Dis 1991;50:642-4.
13. Brogden KA, Guthmiller JM, Taylor CE. Human polymicrobial infections. Lancet 2005;365:253-55.
14. Abbas AK, Lichtman AH. Basic immunology: Functions and disorders of the immune system. Philadelphia, PA: WB Saunders Company, 2001.
15. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, doubleblind clinical trial in 15 patients. Arthritis Rheum 2000;43:1488-95.
16. Kraan MC, Smeets TJ, Van Loon MJ, Breedveld FC, Dijkmans BA, Tak PP. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 2004;63:1056-61.
17. Cutolo M, Sulli A, Ghiorzo P, Pizzorni C, Craviotto C, Villaggio B. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:297-302.
18. van Roon EN, Jansen TL, van de Laar MA et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: Serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:569-74.